Hepato-Gastroenterology, Saint Eloi Hospital, Montpellier, France.
Clin Gastroenterol Hepatol. 2011 Sep;9(9):781-5. doi: 10.1016/j.cgh.2011.05.022. Epub 2011 Jun 6.
BACKGROUND & AIMS: Education of patients with chronic hepatitis C has been proposed to increase response to therapy with peginterferon and ribavirin. We performed a prospective study to determine the effects of systematic consultation by a nurse on patient adherence and the efficacy of therapy.
We analyzed data from 244 patients who received either systematic consultation after each medical visit from a nurse who used a standard evaluation grid and provided information about the disease and treatment (group A [GrA], n = 123) or the conventional clinical follow-up procedure (group B [GrB], n = 121). Treatment lasted 24 to 48 weeks.
Characteristics of each group were similar at baseline, including prior treatment (42.6% in GrA and 36.0% in GrB). Overall, GrA had significantly better adherence to treatment than GrB (74.0% vs 62.8%), especially among patients who received 48 weeks of treatment (69.7% vs 53.2%; P < .03). Significantly more patients in GrA had a sustained virologic response, compared with GrB overall (38.2% vs 24.8%; P < .02), as well as treatment-naive patients (47.1% vs 30.3%; P < .05), and those with genotypes 1, 4, or 5 infections (31.6% vs 13.3%; P < .007). There were no differences between GrA and GrB in response of patients with genotypes 2 or 3 infections or advanced fibrosis. Prognostic factors for a sustained virologic response (based on bivariate and multivariate analyses) were virologic response at week 12 (odds ratio [OR], 1.9; P < .0001), genotypes 2 or 3 (OR, 2.9; P < .0001), therapeutic education (OR, 2.5; P < .02), and lack of previous treatment (OR, 2.3; P < .005).
Therapeutic education by a specialized nurse increases the response of patients with hepatitis C to therapy, particularly in difficult-to-treat patients.
已经提出对慢性丙型肝炎患者进行教育,以提高聚乙二醇干扰素和利巴韦林治疗的反应。我们进行了一项前瞻性研究,以确定护士系统咨询对患者依从性和治疗效果的影响。
我们分析了 244 名接受治疗的患者的数据,这些患者要么在每次就诊后都接受护士的系统咨询,护士使用标准评估表提供有关疾病和治疗的信息(A 组[GrA],n=123),要么接受常规临床随访(B 组[GrB],n=121)。治疗持续 24 至 48 周。
两组患者的基线特征相似,包括既往治疗(42.6%在 GrA 和 36.0%在 GrB)。总体而言,GrA 的治疗依从性明显优于 GrB(74.0%对 62.8%),尤其是接受 48 周治疗的患者(69.7%对 53.2%;P<.03)。与 GrB 相比,GrA 有更多的患者获得持续病毒学应答,总体上(38.2%对 24.8%;P<.02),以及初治患者(47.1%对 30.3%;P<.05),以及基因型 1、4 或 5 感染的患者(31.6%对 13.3%;P<.007)。基因型 2 或 3 感染或晚期纤维化的患者在 GrA 和 GrB 之间的反应没有差异。持续病毒学应答的预测因素(基于双变量和多变量分析)为第 12 周的病毒学应答(比值比[OR],1.9;P<.0001),基因型 2 或 3(OR,2.9;P<.0001),治疗教育(OR,2.5;P<.02),以及无既往治疗(OR,2.3;P<.005)。
专门护士的治疗教育可提高丙型肝炎患者对治疗的反应,特别是在难以治疗的患者中。